• Accueil >
  • Publications >
  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

1 avr. 2020The Lancet Oncology

DOI : 10.1016/s1470-2045(19)30856-3

Auteurs

David S Hong, Steven G DuBois, Shivaani Kummar, Anna F Farago, Catherine M Albert, Kristoffer S Rohrberg, Cornelis M van Tilburg, Ramamoorthy Nagasubramanian, Jordan D Berlin, Noah Federman, Leo Mascarenhas, Birgit Geoerger, Afshin Dowlati, Alberto S Pappo, Stefan Bielack, François Doz, Ray McDermott, Jyoti D Patel, Russell J Schilder, Makoto Tahara, Stefan M Pfister, Olaf Witt, Marc Ladanyi, Erin R Rudzinski, Shivani Nanda, Barrett H Childs, Theodore W Laetsch, David M Hyman, Alexander Drilon